Prenetics (PRE) said Wednesday it has completed the sale of ACT Genomics to Delta Electronics in a deal valued at up to $71.8 million.
The divestment strengthens Prenetics' financial position, raising pro-forma cash reserves to approximately $86 million, the company said.
Prenetics' focus will now shift to growing its high-margin consumer health brands IM8, CircleDNA, and Europa, following the strategic transformation, it said.
Prenetics raised its full-year 2025 revenue guidance to $80-100 million, driven by strong growth in its consumer health segment, the company said.
Shares of the company were up over 10% in recent Wednesday premarket activity.
免责声明：投资有风险，本文并非投资建议，以上内容不应被视为任何金融产品的购买或出售要约、建议或邀请，作者或其他用户的任何相关讨论、评论或帖子也不应被视为此类内容。本文仅供一般参考，不考虑您的个人投资目标、财务状况或需求。TTM对信息的准确性和完整性不承担任何责任或保证，投资者应自行研究并在投资前寻求专业建议。